Pepticom s New Spinout Company, PeptiCov, to Focus on COVID-19
JERUSALEM, March 9, 2021 /PRNewswire/ Pepticom, a leader in artificial intelligence peptide drug design and discovery, announced today that it has raised $2.6 million to establish a company to focus on treatments for the SARS-Cov-2 virus, responsible for the COVID-19 outbreak. The company, PeptiCov, will implement Pepticom s AI technology to design, discover and develop novel peptide molecules for effective treatment of the SARS-Cov-2 virus. The funding round was led by the Chartered Group. Unfortunately, COVID-19 and the various viral mutations will likely be with us for a long time and thus effective treatment is key, said Immanuel Lerner, Founder and CEO of Pepticom. PeptiCov is focused on discovering and developing an effective treatment for SARS-Cov-2, which would allow the world to live alongside the virus rather than remain in lockdowns and other drastic measures.